View More Recent Stories

Feb 6, 2023 09:12AM NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Jan 19, 2023 08:52AM Neurosense Therapeutics (NRSN) Reports Positive Final Results from Alzheimer's Biomarker Study
Jan 19, 2023 08:52AM NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
Dec 1, 2022 09:05AM NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
Nov 16, 2022 09:35AM Neurosense Therapeutics (NRSN) Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
Nov 16, 2022 09:34AM NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
Nov 15, 2022 08:30AM Neurosense Therapeutics (NRSN) Receives FDA Clearance of IND for its ALS Phase 2b Study
Nov 15, 2022 08:30AM NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
Oct 27, 2022 08:50AM NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
Oct 21, 2022 09:25AM NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
Oct 18, 2022 08:33AM NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
Oct 12, 2022 08:30AM NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City
Sep 29, 2022 08:30AM NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
Sep 28, 2022 08:30AM Neurosense Therapeutics (NRSN) Reports Positive PrimeC Pharmacokinetic Study Results, Plans Phase IIb ALS Enrollment to Expand into US
Sep 28, 2022 08:30AM NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
Sep 21, 2022 08:51AM NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Sep 20, 2022 08:45AM Neurosense Therapeutics (NRSN) Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
Sep 20, 2022 08:45AM NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
Sep 19, 2022 09:15AM Neurosense Therapeutics (NRSN) Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Sep 19, 2022 09:14AM NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Aug 31, 2022 09:00AM NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
Aug 2, 2022 08:30AM NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
Jul 28, 2022 09:00AM NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML
Jul 18, 2022 08:30AM NeuroSense Therapeutics CEO Provides Key Corporate Update Video
Jun 30, 2022 08:34AM Neurosense Therapeutics (NRSN) Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
Jun 30, 2022 08:30AM NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study
Jun 27, 2022 08:31AM Neurosense Therapeutics (NRSN) Reports Positive Results from Stage III ALS Biomarker Study
Jun 27, 2022 08:30AM NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Jun 22, 2022 08:30AM NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022
Jun 1, 2022 08:30AM NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC
May 31, 2022 08:30AM NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update
May 23, 2022 08:30AM NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022
Apr 11, 2022 08:30AM NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS
Apr 6, 2022 08:31AM Neurosense Therapeutics (NRSN) Granted Patent in Canada for its ALS Drug PrimeC
Apr 6, 2022 08:30AM NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
Mar 30, 2022 08:24AM Neurosense Therapeutics (NRSN) CEO Provides Key Corporate Update Video
Mar 30, 2022 08:15AM NeuroSense Therapeutics CEO Provides Key Corporate Update Video
Mar 25, 2022 08:01AM Neurosense Therapeutics (NRSN) Announces $4M Financing from Warrant Exercises
Mar 25, 2022 08:00AM NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises
Mar 21, 2022 08:31AM Neurosense Therapeutics (NRSN) Granted FDA Clearance of IND for PrimeC for the Treatment of ALS
Mar 21, 2022 08:30AM NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
Mar 15, 2022 09:00AM NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
Mar 1, 2022 09:03AM Neurosense Therapeutics (NRSN) Granted Key Patent for its ALS Drug PrimeC in Australia
Mar 1, 2022 09:00AM NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia
View More Recent Stories